New Triple-Threat attack on tough lung cancers
NCT ID NCT03377023
Summary
This study is testing whether combining three existing drugs—nivolumab, ipilimumab, and nintedanib—is safe and effective for people with advanced non-small cell lung cancer (NSCLC). It will enroll about 66 adults whose cancer has spread and has no curative treatment options. The first part of the study aims to find the safest dose, and the second part will measure how well the combination shrinks tumors and controls the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.